Pharmacist and Diploma-Pharmacist Eva Göbgen

Eva Göbgen

Institute of Pharmacy

Clinical Pharmacy & Biochemistry

Freie Universität Berlin

Address Kelchstr. 31
Room 242
12169 Berlin
Telephone 030-838 50660
Email eva.goebgen[at]

Curriculum Vitae

since 10/2013

PhD student in the Clinical pharmacy research group headed by Prof. Dr. Charlotte Koft


Registration as pharmacist

11/2012 - 04/2013

pharmaceutical intern at „Apotheke am Hochmeisterplatz“, Berlin

04/2012 - 09/2012

Diploma student in the Clinical Pharmacy Prof. Dr. Charlotte Kloft

02/2009 - 03/2009

clinical elective at „Rathaus Apotheke“, Neunkirchen


clinical elective at „Rathaus Apotheke“, Neunkirchen

10/2007 - 03/2012

Studies of Pharmacy, Freie Universität Berlin


A-levels (Abitur) at Siegtal-Gymnasium Eitorf

Focus of research

[Forschungslinie 1]: Bioanalytics & Microdialysis and Cellculture

The discovery of penicillin by Fleming in 1928 led to the development of antibiotics and represents one of the remarkable achievements in the field of pharmaceutics. Antibiotics allow a potent treatment in the fight against severe infectious diseases such as endocarditis or pneumonia. As a result of their administration, it was possible that, according to the German Federal Statistical Office, the bacterial infections as cause of death in 2012 were far behind cancer and cardiovascular disease. Due to rare new approval of antibiotics and especially the increase in the resistance of bacteria responsible usage of existing antibiotics is becoming increasingly important. Therefore optimised dosing guidelines in the form of patient subgroup-adapted dosage regimens represent a time- and cost-saving method for the use of anti-infectives. In our Dept., the establishment of dosing regimens is based on the pharmacokinetic (PK) and pharmacodynamic (PD) relationships.

The basis of the PK/PD models primarily is either the minimum inhibitory concentration (MIC) as a PK/PD parameter, or the generation of time-kill curves and PK/PD parameters derived from them. The MIC and time-kill curves are determined in vitro in the laboratory. The determination is performed experimentally by in vitro infection models. This determination requires the quantification of bacteria, which is the most time-consuming step in the determination of the respective PK/PD parameter.

My project deals with in vitro determination of MIC and time-kill curves. The determination is performed experimentally with in vitro infection models, which enable a systematic investigation of antibiotic PD for infections caused by bacteria. Taking PK data (drug concentration-time profiles) obtained in clinical trials into account, various scenarios can be mimicked experimentally in vitro, and thereby with the help of PK/PD models recommendations for dosage regimens for the therapeutic practice can be derived. In order to optimise the determination of the parameters, a time- and cost-saving method for the quantification of pathophysiological relevant bacterial species such as Escherichia coli should be developed. This method should be established on the basis of international guidelines such as the EMA guideline for 'Bioanalytical method validation' (2012).